NMRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-05-12), Neumora Therapeutics's share price is $0.6629. Neumora Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Neumora Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:
As of today (2025-05-12), Neumora Therapeutics's share price is $0.6629. Neumora Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.53. Therefore, Neumora Therapeutics's PE Ratio (TTM) for today is At Loss.
As of today (2025-05-12), Neumora Therapeutics's share price is $0.6629. Neumora Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.53. Therefore, Neumora Therapeutics's PE Ratio without NRI for today is At Loss.
The historical data trend for Neumora Therapeutics's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neumora Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | - | - |
Neumora Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Neumora Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Neumora Therapeutics's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Neumora Therapeutics's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 0.6629 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neumora Therapeutics (NAS:NMRA) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Neumora Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Lee Milligan | officer: See Remarks | C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Robert A. Lenz | officer: Head of R&D | C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Paul L Berns | director | 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
Joshua Pinto | officer: Chief Financial Officer | C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Daljit Singh Aurora | officer: Chief Strategy Officer | C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025 |
Matthew K Fust | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Kristina Burow | director, 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Xii, Llc | 10 percent owner | 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners X, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Fund X, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Amgen Inc | 10 percent owner | ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320 |
Henry O Gosebruch | director, officer: President & CEO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
Arch Venture Fund Xii, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Xii, L.p. | 10 percent owner | 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Alaa Halawa | director | C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
From GuruFocus
By Marketwired • 03-30-2025
By Marketwired • 04-02-2025
By PRNewswire • 04-02-2025
By PRNewswire • 04-04-2025
By PRNewswire • 04-04-2025
By Marketwired • 04-01-2025
By Marketwired • 04-07-2025
By Marketwired • 04-07-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.